文献速递妇科肿瘤

MITO END-3:基于分子谱分析评估阿维鲁单抗免疫治疗在一线子宫内膜癌治疗中的疗效

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
PubMed 文献 · Ann Oncol · 2024-05-03

MITO END-3 试验的预设转化分析评估了基因组异常对阿维鲁单抗联合卡铂/紫杉醇一线治疗晚期子宫内膜癌患者疗效的影响。在 125 例随机患者中,109 例样本可进行下一代测序分析,102 例进行了微卫星不稳定性检测。结果显示,TP53 突变与阿维鲁单抗疗效差相关,而 PTEN 和 ARID1A 突变与药物阳性效应相关。

要点

  • 在 MSI-H 和 MSS/TP53 突变型中,阿维鲁单抗对 PFS 的效应显著不同(交互作用 P=0.003)。
  • ARID1A 和 PTEN 突变与治疗效应存在统计学显著交互作用(P 交互分别为 0.01 和 0.002)。
  • TP53 突变与阿维鲁单抗疗效差相关,PTEN 和 ARID1A 突变与阳性效应相关。

核心结论

  • MITO END-3 试验结果表明,TP53 突变与阿维鲁单抗疗效差相关,而 PTEN 和 ARID1A 突变与晚期子宫内膜癌患者对该药的阳性效应相关。

研究设计与样本

  • MITO END-3 试验的预设转化分析,纳入 125 例随机患者,其中 109 例样本可进行下一代测序分析,102 例进行了微卫星不稳定性检测。

主要发现

  • 根据 TCGA 分型,29 例为 MSI-H,26 例为 MSS TP53 野生型,47 例为 MSS TP53 突变型,1 例为 POLE 突变。
  • 11 例(10%)存在 BRCA1/2 突变(MSI-H 中 5 例,MSS 中 6 例)。
  • 高肿瘤突变负荷(≥10 muts/Mb)见于所有 MSI-H 患者、47 例 MSS/TP53 突变型中的 4 例,以及 MSS/TP53 野生型中无病例。
  • 阿维鲁单抗对 PFS 的效应根据 TCGA 分型显著不同,在 MSI-H 中有利,在 MSS/TP53 突变型中最差(交互作用 P=0.003);生存分析中可见类似但非显著的趋势。
  • ARID1A 和 PTEN 与治疗效应存在统计学显著交互作用,存在突变时疗效更好(ARID1A 交互作用 P=0.01;PTEN 交互作用 P=0.002)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy combined with chemotherapy significantly improves progression-free survival (PFS) compared to first-line chemotherapy alone in advanced endometrial cancer (EC), with a much larger effect size in microsatellite instability-high (MSI-H) cases. New biomarkers might help to select patients who may have benefit among those with a microsatellite-stable (MSS) tumor. PATIENTS AND METHODS: In a pre-planned translational analysis of the MITO END-3 trial, we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab. RESULTS: Out of 125 randomized patients, 109 had samples eligible for next-generation sequencing analysis, and 102 had MSI tested. According to The Cancer Genome Atlas (TCGA), there were 29 cases with MSI-H, 26 with MSS TP53 wild type (wt), 47 with MSS TP53 mutated (mut), and 1 case with POLE mutation. Four mutated genes were present in >30% of cases: TP53, PIK3CA, ARID1A, and PTEN. Eleven patients (10%) had a BRCA1/2 mutation (five in MSI-H and six in MSS). High tumor mutational burden (≥10 muts/Mb) was observed in all MSI-H patients, in 4 out of 47 MSS/TP53 mut, and no case in the MSS/TP53 wt category. The effect of avelumab on PFS significantly varied according to TCGA categories, being favorable in MSI-H and worst in MSS/TP53 mut (P interaction = 0.003); a similar non-significant trend was seen in survival analysis. ARID1A and PTEN also showed a statistically significant interaction with treatment effect, which was better in the presence of the mutation (ARID1A P interaction = 0.01; PTEN P interaction = 0.002). CONCLUSION: The MITO END-3 trial results suggest that TP53 mutation is associated with a poor effect of avelumab, while mutations of PTEN and ARID1A are related to a positive effect of the drug in patients with advanced EC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Pignata S, Califano D, Lorusso D, et al. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Ann Oncol. 2024. PMID: 38704093. doi:10.1016/j.annonc.2024.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。